Alprazolam Tablets — Class II drug recall D-0458-2023
Terminated recall by Breckenridge Pharmaceutical, Inc, reported 2023-03-22, distributed nationwide. CGMP Deviations: Potential risk of Cross Contamination
| Recall number | D-0458-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Breckenridge Pharmaceutical, Inc, Berlin, CT, United States |
| Recall initiated | 2023-03-02 |
| Classified | 2023-03-10 |
| Reported by FDA | 2023-03-22 |
| Terminated | 2024-03-21 |
| Distributed | Nationwide (US) |
| Reason classes | cgmp |
| NDC | 51991-0704-01 |
| Expiration dates | 2020-05-31, 2023-04-30, 2023-05-31, 2023-06-30, 2024-07-31, 2024-08-31, 2024-10-31, 2025-04-30 |
Product
Alprazolam Tablets, USP, 0.25mg, CIV, packaged in: a) 100-count bottle (NDC 51991-0704-01), b) 500-count bottle and c) 1,000-count bottle, Rx only, Manufactured by Centaur Pharmaceuticals PVT. LTD., Hinjewadi, Pune, INDIA, Distributed by: Breckenridge Pharmaceuticals, Inc., Berlin, CT 06037.
Reason for recall
CGMP Deviations: Potential risk of Cross Contamination
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0458-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.